Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer

Multiple Cancer Types

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). Approximately 520 subjects will be randomized to one of the following treatment arms in a 2:1 ratio, fruquintinib plus BSC or placebo plus BSC.
Colon, Rectal
III
Eng, Cathy
NCT04322539
VICCGI2045

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: